-
Mashup Score: 0Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer | GSK US - 10 day(s) ago
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab-gxly.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: Today at #ASH24, we presented positive results from our phase III clinical trial evaluating one of our #bloodcancer treatments. Learn more: https://t.co/AwZrdtqB0q https://t.co/boMzOULmqp
-
-
Mashup Score: 3US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD | GSK US - 17 day(s) ago
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #investors and #media: Today we have announced the FDA has accepted the submission for one of our biologics in chronic obstructive pulmonary disease (#COPD). Learn more here: https://t.co/BBElA0p6Ij https://t.co/z5SRDDMLhf
-
-
Mashup Score: 3Belantamab mafodotin combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma | GSK US - 1 month(s) ago
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: The @US_FDA has accepted our application for one of our #bloodcancer therapies in combination with standards of care. Learn more: https://t.co/X58XIBjc7P https://t.co/GDOmI3eTvl
-
-
Mashup Score: 6Creating a Culture of Holistic Care in Lupus | GSK US - 1 month(s) ago
Lupus is a disease that flares and damages vital organs, GSK aims to improve lives through holistic care and a culture of health.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
Social factors can majorly impact a person’s health, especially for people from racial & ethnic minority groups living with #lupus. GSK is addressing these challenges & encouraging early intervention for those living with this condition: https://t.co/WfEM50i2Nv @ACRheum #ACR24 https://t.co/sirV5ETTZV
-
-
Mashup Score: 4Home | GSK - 2 month(s) ago
At GSK, we unite science, technology and talent to get ahead of disease together
Source: www.gsk.comCategories: General Medicine News, PayerTweet-
RT @GSK: News for #Investors and #Media Explore our full year 2023 figures at a glance. Dive into the data: https://t.co/iq6ccrYH5Q. $GSK…
-
-
Mashup Score: 2Respiratory/ immunology | GSK - 2 month(s) ago
We are advancing the frontiers of respiratory science and leveraging our understanding of the immune system to transform patient outcomes.
Source: www.gsk.comCategories: General Medicine News, PayerTweet-
We’re excited to be at @ASNKidney week. As long-standing leaders in the #lupus community, we know how critical disease management is to try to help reduce organ damage progression for patients. Learn more: https://t.co/eFwdkoCHQ5 #KidneyWk https://t.co/DPHXzRIvl3
-
-
Mashup Score: 11GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S. | GSK US - 2 month(s) ago
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
We’re proud to be investing in US manufacturing to bring products and innovation to patients faster. Thanks to @GovernorShapiro, @DCEDSecretary, @SenatorAument and PA Rep Tom Jones for helping to make our Marietta Pennsylvania site expansion possible! https://t.co/vjpnOWTlc6 https://t.co/ID2nQInPNX
-
-
Mashup Score: 11GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S. | GSK US - 2 month(s) ago
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
Breaking #News: We are making our largest US manufacturing investment to date: $800 million in our Pennsylvania site, able to manufacture both medicines and vaccines, double the size of the site and over 200 new jobs. Read more here: https://t.co/WsiKOrp6Mx https://t.co/0xIjRIzwkx
-
-
Mashup Score: 0
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: Today we shared data on our RSV vaccine. Learn more: https://t.co/eWswjH425L https://t.co/ce8HwWtvDC
-
#News for #Investors and #Media: The FDA has granted Breakthrough Therapy Designation to one of our immuno-oncology treatments. Learn more: https://t.co/bVm8UoqCfe https://t.co/rAJXo9XJ1V